Translations:SGLT2 inhibitor/14/en

Members

These are the known members of the gliflozin class:

• Bexagliflozin was approved in the United States under the brand name Brenzavvy in January 2023.
• Canagliflozin was the first SGLT2 inhibitor to be approved for use in the United States. It was approved in March 2013, under the brand name Invokana and it was also marketed throughout the EU under the same name.
• Dapagliflozin, approved under the name Forxiga, was approved by the EU in 2012, the first SGLT2 inhibitor approved anywhere. It was approved for use in the United States under the brand name Farxiga by the FDA in January 2014. It was the first oral treatment, in combination with insulin, to treat type 1 diabetes in the UK and EU.
• Empagliflozin, approved in the United States in August 2014, under the brand name Jardiance by Boehringer Ingelheim. Of the gliflozins, empagliflozin and tofogliflozin have the highest specificity for SGLT2 inhibition. This oral medicine for type 2 diabetes has been shown to reduce the risk of cardiovascular death.
• Ertugliflozin was approved in the United States under the brand name Steglatro in December 2017.
• Ipragliflozin, produced by the Japanese company Astellas Pharma Inc. under the brand name Suglat, approved in Japan January 2014.
• Luseogliflozin, developed by Taisho Pharmaceutical, was approved in Japan in March 2014 under the brand name Lusefi.
• Remogliflozin etabonate was commercially launched first in India by Glenmark in May 2019.
• Sergliflozin etabonate discontinued after Phase II trials.
• Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the FDA in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
• Tofogliflozin, developed by Sanofi and Kowa Pharmaceutical, was approved in Japan in March 2014, under the brand names Apleway and Deberza.
• Henagliflozin, selective SGLT2 inhibitor. Approved in China.
• Janagliflozin.
• Mizagliflozin
• Velagliflozin Proline hydrate
• Enavogliflozin